{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:33:37Z","timestamp":1734500017252,"version":"3.30.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"DOI":"10.7759\/cureus.75874","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T15:26:45Z","timestamp":1734449205000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Diagnoses and Characterization of Patients With Amyloid-Negative Amyloid-Beta, p-Tau, and Neurofilament Light Chain (ATN) Profiles"],"prefix":"10.7759","author":[{"given":"Colin","family":"Barnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiel","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330619","article-title":"Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic","volume":"94","author":"Altomare D","year":"2023","unstructured":"Altomare D, Stampacchia S, Ribaldi F, et al.. Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry. 2023, 94:420-7. 10.1136\/jnnp-2022-330619","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12465","article-title":"Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease","volume":"15","author":"Giangrande C","year":"2023","unstructured":"Giangrande C, Delatour V, Andreasson U, Blennow K, Gobom J, Zetterberg H. Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease. Alzheimers Dement (Amst). 2023, 15:e12465. 10.1002\/dad2.12465","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al.. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018, 14:535-62. 10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00365-x","article-title":"Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints","volume":"12","author":"Lu J","year":"2023","unstructured":"Lu J, Ma X, Zhang H, et al.. Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints. Transl Neurodegener. 2023, 12:34. 10.1186\/s40035-023-00365-x","journal-title":"Transl Neurodegener"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"20","author":"Schindler SE","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, et al.. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. Nat Rev Neurol. 2024, 20:426-39. 10.1038\/s41582-024-00977-5","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2338","article-title":"Prevalence and clinical implications of a \u03b2-amyloid-negative, tau-positive cerebrospinal fluid biomarker profile in Alzheimer disease","volume":"80","author":"Erickson P","year":"2023","unstructured":"Erickson P, Simr\u00e9n J, Brum WS, et al.. Prevalence and clinical implications of a \u03b2-amyloid-negative, tau-positive cerebrospinal fluid biomarker profile in Alzheimer disease. JAMA Neurol. 2023, 80:969-79. 10.1001\/jamaneurol.2023.2338","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2023.03.007","article-title":"The clinical application of optimized AT(N) classification in Alzheimer's clinical syndrome (ACS) and non-ACS conditions","volume":"127","author":"Kasuga K","year":"2023","unstructured":"Kasuga K, Tsukie T, Kikuchi M, et al.. The clinical application of optimized AT(N) classification in Alzheimer's clinical syndrome (ACS) and non-ACS conditions. Neurobiol Aging. 2023, 127:23-32. 10.1016\/j.neurobiolaging.2023.03.007","journal-title":"Neurobiol Aging"},{"key":"ref8","article-title":"Blood-based biomarkers in Alzheimer disease: clinical implementation and limitations","author":"Pleen J","year":"2024","unstructured":"Pleen J, Camerucci E, Al-Sabbagh MQ, Cunningham K. Blood-based biomarkers in Alzheimer disease: clinical implementation and limitations. Pract Neurol. 2024, 27-42.","journal-title":"Pract Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simr\u00e9n J","year":"2021","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, et al.. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement. 2021, 17:1145-56. 10.1002\/alz.12283","journal-title":"Alzheimers Dement"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02408-5","article-title":"Plasma biomarkers for Alzheimer's disease in relation to neuropathology and cognitive change","volume":"143","author":"Smirnov DS","year":"2022","unstructured":"Smirnov DS, Ashton NJ, Blennow K, et al.. Plasma biomarkers for Alzheimer's disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022, 143:487-503. 10.1007\/s00401-022-02408-5","journal-title":"Acta Neuropathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12026","article-title":"Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative","volume":"12","author":"Allegri RF","year":"2020","unstructured":"Allegri RF, Chrem M\u00e9ndez P, Calandri I, et al.. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement (Amst). 2020, 12:e12026. 10.1002\/dad2.12026","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa165","article-title":"ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration","volume":"143","author":"Cousins KA","year":"2020","unstructured":"Cousins KA, Irwin DJ, Wolk DA, et al.. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. Brain. 2020, 143:2295-311. 10.1093\/brain\/awaa165","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200900","article-title":"Blood-based ATN biomarkers of Alzheimer\u2019s disease: a meta-analysis","volume":"79","author":"Koychev I","year":"2021","unstructured":"Koychev I, Jansen K, Dette A, Shi L, Holling H. Blood-based ATN biomarkers of Alzheimer\u2019s disease: a meta-analysis. J Alzheimers Dis. 2021, 79:177-95. 10.3233\/JAD-200900","journal-title":"J Alzheimers Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021371","article-title":"The synergic effect of AT(N) profiles and depression on the risk of conversion to dementia in patients with mild cognitive impairment","volume":"24","author":"Marqui\u00e9 M","year":"2023","unstructured":"Marqui\u00e9 M, Garc\u00eda-Guti\u00e9rrez F, Orellana A, et al.. The synergic effect of AT(N) profiles and depression on the risk of conversion to dementia in patients with mild cognitive impairment. Int J Mol Sci. 2023, 24:10.3390\/ijms24021371","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12174","article-title":"Adding cognition to AT(N) models improves prediction of cognitive and functional decline","volume":"13","author":"O'Shea DM","year":"2021","unstructured":"O'Shea DM, Thomas KR, Asken B, et al.. Adding cognition to AT(N) models improves prediction of cognitive and functional decline. Alzheimers Dement (Amst). 2021, 13:e12174. 10.1002\/dad2.12174","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2023.11.002","article-title":"Disease trajectories in older adults with non-AD pathologic change and comparison with Alzheimer's disease pathophysiology: a longitudinal study","volume":"134","author":"Li JQ","year":"2024","unstructured":"Li JQ, Song JH, Suckling J, et al.. Disease trajectories in older adults with non-AD pathologic change and comparison with Alzheimer's disease pathophysiology: a longitudinal study. Neurobiol Aging. 2024, 134:106-14. 10.1016\/j.neurobiolaging.2023.11.002","journal-title":"Neurobiol Aging"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00621-6","article-title":"Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia","volume":"12","author":"Tan MS","year":"2020","unstructured":"Tan MS, Ji X, Li JQ, et al.. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. Alzheimers Res Ther. 2020, 12:55. 10.1186\/s13195-020-00621-6","journal-title":"Alzheimers Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14357","article-title":"Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework","volume":"30","author":"Xiong X","year":"2024","unstructured":"Xiong X, He H, Ye Q, et al.. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework. CNS Neurosci Ther. 2024, 30:e14357. 10.1111\/cns.14357","journal-title":"CNS Neurosci Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009724","article-title":"ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project","volume":"95","author":"Ebenau JL","year":"2020","unstructured":"Ebenau JL, Timmers T, Wesselman LM, et al.. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology. 2020, 95:e46-58. 10.1212\/WNL.0000000000009724","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26151-8","article-title":"The A\/T\/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment","volume":"8","author":"Ekman U","year":"2018","unstructured":"Ekman U, Ferreira D, Westman E. The A\/T\/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. Sci Rep. 2018, 8:8431. 10.1038\/s41598-018-26151-8","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01653-8","article-title":"Prefrontal A\u03b2 pathology influencing the pathway from apathy to cognitive decline in non-dementia elderly","volume":"11","author":"Sun L","year":"2021","unstructured":"Sun L, Li W, Li G, Xiao S. Prefrontal A\u03b2 pathology influencing the pathway from apathy to cognitive decline in non-dementia elderly. Transl Psychiatry. 2021, 11:534. 10.1038\/s41398-021-01653-8","journal-title":"Transl Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-019-00148-5","article-title":"Diagnosing and treating depression in patients with Alzheimer\u2019s disease","volume":"8","author":"Burke AD","year":"2019","unstructured":"Burke AD, Goldfarb D, Bollam P, Khokher S. Diagnosing and treating depression in patients with Alzheimer\u2019s disease. Neurol Ther. 2019, 8:325-50. 10.1007\/s40120-019-00148-5","journal-title":"Neurol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1192562","article-title":"Early-onset Alzheimer's disease with depression as the first symptom: a case report with literature review","volume":"14","author":"Liu M","year":"2023","unstructured":"Liu M, Xie X, Xie J, Tian S, Du X, Feng H, Zhang H. Early-onset Alzheimer's disease with depression as the first symptom: a case report with literature review. Front Psychiatry. 2023, 14:1192562. 10.3389\/fpsyt.2023.1192562","journal-title":"Front Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.74248","article-title":"The complex relationship between depression and dementia","volume":"13","author":"Muliyala KP","year":"2010","unstructured":"Muliyala KP, Varghese M. The complex relationship between depression and dementia. Ann Indian Acad Neurol. 2010, 13:S69-73. 10.4103\/0972-2327.74248","journal-title":"Ann Indian Acad Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton NJ","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al.. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024, 81:255-63. 10.1001\/jamaneurol.2023.5319","journal-title":"JAMA Neurol"},{"key":"ref26","unstructured":"Labcorp. Phosphorylated tau 217 (pTau-217), plasma. (2024). Accessed: July 12, 2024: https:\/\/www.labcorp.com\/tests\/484390\/phosphorylated-tau-217-ptau-217-plasma."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen NC","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S, et al.. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021, 12:3555. 10.1038\/s41467-021-23746-0","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12706","article-title":"Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models","volume":"19","author":"Cullen NC","year":"2023","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, et al.. Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimers Dement. 2023, 19:797-806. 10.1002\/alz.12706","journal-title":"Alzheimers Dement"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1429211","article-title":"Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics","volume":"16","author":"Abdul Manap AS","year":"2024","unstructured":"Abdul Manap AS, Almadodi R, Sultana S, Sebastian MG, Kavani KS, Lyenouq VE, Shankar A. Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics. Front Aging Neurosci. 2024, 16:1429211. 10.3389\/fnagi.2024.1429211","journal-title":"Front Aging Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson O","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, et al.. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022, 18:2669-86. 10.1002\/alz.12756","journal-title":"Alzheimers Dement"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281998-clinical-diagnoses-and-characterization-of-patients-with-amyloid-negative-amyloid-beta-p-tau-and-neurofilament-light-chain-atn-profiles","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T15:26:48Z","timestamp":1734449208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281998-clinical-diagnoses-and-characterization-of-patients-with-amyloid-negative-amyloid-beta-p-tau-and-neurofilament-light-chain-atn-profiles"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.75874","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}